**The administrative record for broader marijuana rescheduling closed in mid-July 2026 after an expedited DEA hearing that ran from June 29 to July 15.** Opponents including Smart Approaches to Marijuana participated, but key testimony included concessions that cannabis meets Schedule III criteria under the Controlled Substances Act. In September 2026 a federal appeals court rejected challenges seeking to block the April 2026 final order that already moved state-licensed medical marijuana and FDA-approved products to Schedule III, allowing that change to remain in effect during litigation. The DEA has defended the proposal in post-hearing briefs, citing widespread state medical programs and accepted safety under supervision. An administrative law judge recommendation is expected later in 2026, followed by a final DEA Administrator decision and likely court review. These procedural steps and the possibility of delays from appeals or agency timelines shape trader assessments of completion dates for full rescheduling from Schedule I.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update$812,403 Vol.
Dec 31, 2026
September 30
2%
December 31
22%
$812,403 Vol.
September 30
$739 Vol.
2%
December 31
$202,093 Vol.
22%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The administrative record for broader marijuana rescheduling closed in mid-July 2026 after an expedited DEA hearing that ran from June 29 to July 15.** Opponents including Smart Approaches to Marijuana participated, but key testimony included concessions that cannabis meets Schedule III criteria under the Controlled Substances Act. In September 2026 a federal appeals court rejected challenges seeking to block the April 2026 final order that already moved state-licensed medical marijuana and FDA-approved products to Schedule III, allowing that change to remain in effect during litigation.
The DEA has defended the proposal in post-hearing briefs, citing widespread state medical programs and accepted safety under supervision. An administrative law judge recommendation is expected later in 2026, followed by a final DEA Administrator decision and likely court review. These procedural steps and the possibility of delays from appeals or agency timelines shape trader assessments of completion dates for full rescheduling from Schedule I.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Binuksan ang Market: Feb 7, 2026, 5:04 PM ET
Volume
$812,403Petsa ng Pagtatapos
Jan 1, 2027Binuksan ang Market
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The administrative record for broader marijuana rescheduling closed in mid-July 2026 after an expedited DEA hearing that ran from June 29 to July 15.** Opponents including Smart Approaches to Marijuana participated, but key testimony included concessions that cannabis meets Schedule III criteria under the Controlled Substances Act. In September 2026 a federal appeals court rejected challenges seeking to block the April 2026 final order that already moved state-licensed medical marijuana and FDA-approved products to Schedule III, allowing that change to remain in effect during litigation.
The DEA has defended the proposal in post-hearing briefs, citing widespread state medical programs and accepted safety under supervision. An administrative law judge recommendation is expected later in 2026, followed by a final DEA Administrator decision and likely court review. These procedural steps and the possibility of delays from appeals or agency timelines shape trader assessments of completion dates for full rescheduling from Schedule I.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$812,403Petsa ng Pagtatapos
Jan 1, 2027Binuksan ang Market
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The administrative record for broader marijuana rescheduling closed in mid-July 2026 after an expedited DEA hearing that ran from June 29 to July 15.** Opponents including Smart Approaches to Marijuana participated, but key testimony included concessions that cannabis meets Schedule III criteria under the Controlled Substances Act. In September 2026 a federal appeals court rejected challenges seeking to block the April 2026 final order that already moved state-licensed medical marijuana and FDA-approved products to Schedule III, allowing that change to remain in effect during litigation. The DEA has defended the proposal in post-hearing briefs, citing widespread state medical programs and accepted safety under supervision. An administrative law judge recommendation is expected later in 2026, followed by a final DEA Administrator decision and likely court review. These procedural steps and the possibility of delays from appeals or agency timelines shape trader assessments of completion dates for full rescheduling from Schedule I.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong